In Wednesday’s Wall Street session, Nuvation Bio Inc (NYSE:NUVB) shares traded at $1.79, up 4.68% from the previous session.
NUVB stock price is now -16.12% away from the 50-day moving average and -24.86% away from the 200-day moving average. The market capitalization of the company currently stands at $609.07M.
With the price target of $6, Citizens JMP recently initiated with Mkt Outperform rating for Nuvation Bio Inc (NYSE: NUVB). On March 27, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $1.40 to quote $10, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Markel Stacy, CHIEF PEOPLE OFFICER bought 10,000 shares of the company’s stock on Jun 18 ’25. The stock was bought for $17,100 at an average price of $1.71. Upon completion of the transaction, the CHIEF PEOPLE OFFICER now directly owns 29,591 shares in the company, valued at $52967.89. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17 ’25, Chief Financial Officer Sauvage Philippe bought 4,000 shares of the business’s stock. A total of $7,160 was incurred on buying the stock at an average price of $1.79. This leaves the insider owning 9,902 shares of the company worth $17724.58. A total of 33.36% of the company’s stock is owned by insiders.
During the past 12 months, Nuvation Bio Inc has had a low of $1.54 and a high of $3.97. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 9.01, and a quick ratio of 9.01. The fifty day moving average price for NUVB is $2.134 and a two-hundred day moving average price translates $2.3821 for the stock.
The latest earnings results from Nuvation Bio Inc (NYSE: NUVB) was released for 2025-03-31. The net profit margin was -5534.21% and return on equity was -119.66% for NUVB.
